CLARKE JOHN K 4
4 · aTYR PHARMA INC · Filed Apr 28, 2023
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
CLARKE JOHN K
DirectorOther
Transactions
- Exercise/Conversion
Common Stock
2023-04-26+6,000→ 19,797 total - Exercise/Conversion
Restricted Stock Unit
2023-04-26−6,000→ 0 total→ Common Stock (0 underlying)
Footnotes (4)
- [F1]Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022.
- [F2]RSUs convert into common stock on a one-for-one basis.
- [F3]Includes 6,305 shares received as a pro-rata distribution on September 28, 2021 (the "Liquidating Distribution") from CHP II, L.P., in which the Reporting Person is a managing partner. In prior reports, the reporting person reported beneficial ownership of 108,083 shares of aTyr Pharma common stock held by CHP II, L.P., which are no longer held as of September 28, 2021 due to the Liquidating Distribution.
- [F4]The RSUs fully vested one year from the grant date which was April 26, 2022.